无并发症B型主动脉夹层的真实世界结局与管理趋势
基于日本静冈国保数据库纳入1292例无并发症B型主动脉夹层患者,1年累积死亡率为15.0%,显著高于年龄性别匹配的一般人群的6.7%。1、2、3年主动脉事件率分别为22.1%、30.0%、36.7%。12个月内TEVAR与较低死亡率和较少主动脉事件呈趋势相关,但未达统计学显著性。
要点
- 无并发症B型主动脉夹层1年累积死亡率15.0%,高于一般人群的6.7%。
- 1、2、3年主动脉事件率分别为22.1%、30.0%、36.7%。
- 12个月内TEVAR与较低死亡和主动脉事件呈趋势相关,但置信区间含1。
核心结论
- 无并发症B型主动脉夹层患者生存率低于一般人群且主动脉事件率较高。
- 12个月内TEVAR可能改善患者结局,但关联未达统计学显著性。
研究设计与样本
- 基于日本静冈国保数据库的区域性理赔数据库回顾性分析。
- 纳入2013年4月1日至2020年9月30日因急性TBAD入院且年龄≥20岁的患者,入院1个月后分类为uTBAD,共1292例。
- TEVAR与药物治疗比较采用逆概率加权。
主要发现
- 累积死亡率显著高于年龄和性别校正的一般人群(1年:15.0% vs 6.7%,3年:28.6% vs 18.6%,P < 0.001)。
- 1、2、3年主动脉事件率分别为22.1%、30.0%、36.7%。
- 12个月内TEVAR与较低死亡率呈趋势相关(校正风险比0.53,95%CI 0.27-1.04)。
- 12个月内TEVAR与较少主动脉事件呈趋势相关(校正风险比0.54,95%CI 0.29-1.01)。
临床怎么用
- 对无并发症B型主动脉夹层患者应认识到其长期死亡和主动脉事件风险高于一般人群。
- 12个月内TEVAR可作为改善结局的潜在选择,但需结合个体情况权衡。
局限性
- 数据来源于区域性理赔数据库,可能存在编码偏倚和未测量混杂。
- TEVAR与药物治疗的比较为观察性分析,关联未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Uncomplicated type B aortic dissection (uTBAD) accounts for a significant proportion of TBAD cases, but large-scale data on their prognosis remain limited. This study aims to evaluate real-world management and outcomes of uTBAD. METHODS: Patients aged 20 or older admitted for acute TBAD between 1 April 2013 and 30 September 2020 were included in the analysis set. They were classified as uTBAD 1 month after admission. Data were sourced from the Shizuoka Kokuho Database, a regional claims database. The primary outcomes were all-cause mortality and aortic events (death, type A dissection, rupture or surgery). Cumulative event rates were estimated using the Kaplan-Meier method. Outcomes of patients treated with thoracic endovascular aortic repair (TEVAR) versus medical therapy were compared using inverse probability weighting. RESULTS: A total of 1292 uTBAD patients were identified. Sixty-seven patients underwent TEVAR within 12 months, with a cumulative TEVAR rate of 5.4%. The cumulative mortality was significantly higher in comparison to the age- and sex-adjusted general population (1 year: 15.0% vs 6.7%, 3 years: 28.6% vs 18.6%, P < 0.001). Aortic events occurred in 22.1%, 30.0% and 36.7% at 1, 2 and 3 years, respectively. TEVAR within 12 months was associated with a trend towards lower mortality (adjusted hazard ratio 0.53, 95% confidence interval 0.27-1.04) and fewer aortic events (adjusted hazard ratio 0.54, 95% confidence interval 0.29-1.01) compared to medical therapy. CONCLUSIONS: uTBAD patients have poorer survival and higher rates of aortic events compared to the general population. TEVAR within 12 months can potentially improve patient outcomes.
引用
- Ueki C, Nakatani E, Sugawara A, et al. Real-world outcomes and management trends in uncomplicated type B aortic dissection. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40215183. doi:10.1093/icvts/ivaf089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。